biote Corp Dossier
Qualitative Analysis
Business overview
biote Corp. (Nasdaq: BTMD) is a leading provider of innovative hormone optimization and healthy aging solutions that focus on advancing the healthspan of patients. Operating a comprehensive, end-to-end practice-building platform, Biote provides medical practitioners with clinical training, certification, practice management software, and marketing support to successfully implement the Biote Method. The company's business model is built on long-term service agreements with practitioners (procedure-based service fees) and the sale of Biote-branded dietary supplements. As of late 2025, Biote's network supported over 9,200 contracted practitioners across more than 5,300 clinics, serving approximately 400,000 active patients with a high practitioner retention rate exceeding 91%.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the field sales force to approximately 120 representatives to enhance sales coverage, stabilize clinic attrition, and maximize new clinic starts.
Expected impact: Aims to accelerate practitioner onboarding, drive new clinic growth, and restore sustainable procedure revenue growth.
Investing in the proprietary clinical decision support software and digital platform to enhance practitioner experience and retention.
Expected impact: Improves clinic-to-patient engagement, clinical decision accuracy, and practitioner satisfaction to lower historical attrition rates.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Enables vertical integration of compounded bioidentical hormone pellet manufacturing, strengthening supply chain control and pharmacokinetic research.
Financial impact: Improves long-term gross margin profile through insourced manufacturing, despite a temporary $1.3 million inventory charge in Q4 2025 and $1.1 million incremental recall costs in Q1 2026.
Acquisition of certain intellectual property and intellectual property rights to enhance the company's clinical software and digital platform capabilities.
Financial impact: Paid $1.5 million in cash and 389,105 shares of Class A common stock, with an outstanding earnout liability valued at $2.0 million as of Q1 2026.
Acquisition of certain assets to support strategic growth initiatives and expand customer relationships.
Financial impact: Paid $0.7 million in cash with a potential future earnout of up to $0.1 million based on operating metrics.